Trends in Contrast Media

[1]  A. Sundin,et al.  Efficacy of the hepatocyte-specific contrast medium FP 736-04 for CT in two models of experimental diffuse liver disease. , 1998, Academic radiology.

[2]  V. Lorusso,et al.  Safety and pharmacokinetics of BR21, a liver-specific CT agent, in healthy volunteers. , 1998, Academic radiology.

[3]  G. Schuhmann-Giampieri,et al.  Dysprosium EOB DTPA: a new liver-specific contrast agent for computed tomography. , 1998, Academic radiology.

[4]  A. Magnusson,et al.  Contrast enhancement of the liver in healthy male volunteers following intravenous administration of FP 736-04. , 1998, Academic radiology.

[5]  S. Schmitz,et al.  A prototype liver-specific contrast medium for CT: preclinical evaluation of gadoxetic acid disodium, or Gd-EOB-DTPA. , 1997, Radiology.

[6]  D. Keppler,et al.  Introduction: Transport across the hepatocyte canalicular membrane , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  G. Gazelle,et al.  Functional CT with an experimental intravascular contrast agent in the assessment of liver vascular physiology. , 1996, Academic radiology.

[8]  F. Lee,et al.  Computed tomography scanning of Morris hepatomas with liver-specific polyiodinated triglycerides. , 1996, Academic radiology.

[9]  P. Leander.  A New Liposomal Contrast Medium for CT of the Liver , 1996 .

[10]  U. Schmiedl,et al.  Liver contrast enhancement in primates using iopromide liposomes. , 1995, Academic radiology.

[11]  S E Seltzer,et al.  Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions. , 1995, Radiology.

[12]  E F Halpern,et al.  Nanoparticulate computed tomography contrast agents for blood pool and liver-spleen imaging. , 1994, Academic radiology.

[13]  G. Gazelle,et al.  Nanocrystalline computed tomography contrast agents for blood-pool and liver-spleen imaging. , 1994, Investigative radiology.

[14]  C. Claussen,et al.  Superparamagnetic iron oxide: Detection of focal liver lesions at high‐field‐strength MR imaging , 1994, Journal of magnetic resonance imaging : JMRI.

[15]  G. Schuhmann-Giampieri,et al.  Characterization of Iopromide Liposomes , 1993, Investigative radiology.

[16]  D. Carney,et al.  Perfluorooctylbromide as a contrast agent for CT and sonography: preliminary clinical results. , 1993, AJR. American journal of roentgenology.

[17]  R. M. Peters,et al.  Characterization and Mechanism of Side‐Effects of Imagent BP (highly concentrated fluorocarbon emulsion) in Swine , 1991, Investigative radiology.

[18]  A. Burgess,et al.  Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. , 1990, Cancer research.

[19]  T J O'Leary,et al.  CT of the liver and spleen with EOE-13: review of 225 examinations. , 1984, AJR. American journal of roentgenology.

[20]  I. Raynal,et al.  Nonionic compact dimers: a new generation of isosmolar iodinated contrast media with low viscosity. , 1998, Academic radiology.

[21]  G. Gazelle,et al.  Block-copolymer of polyethylene glycol and polylysine as a carrier of organic iodine: design of long-circulating particulate contrast medium for X-ray computed tomography. , 1997, Journal of drug targeting.

[22]  R. M. Peters,et al.  Characterization and mechanism of side-effects of Oxygent HT (highly concentrated fluorocarbon emulsion) in swine. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[23]  T. Yaksh,et al.  Influence of perflubron emulsion particle size on blood half-life and febrile response in rats. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[24]  C. Balu-Maestro,et al.  Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. , 1989, Radiology.